Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Condition(s) studied
Investigational drug(s) / intervention(s)
Adjustable Continence Therapy for Women (ACT): Two ACT devices are implanted in each patient. The devices are intended for implantation in the paraurethral space, with the balloons located on each side of the urethra near the bladder neck. The ports are placed subcutaneously in the labia majora. The balloons are filled after implantation with an isotonic solution via needle injection into the port. The ACT implant can be placed using local, spinal or general anesthesia with the surgical instruments (provided separately).
Study summary
A prospective, single arm, non-randomized, multicenter, prospective case-series trial. The purpose of this trial is to demonstrate the safety and effectiveness of using the Adjustable Continence Therapy (ACT) to provide a clinically relevant improvement in stress urinary incontinence.
Eligibility
Primary outcome measure(s)
- Provocative pad weight — 12 months
Change in provocative pad weight from baseline
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| University of Colorado | Denver | Colorado | Recruiting |
| Idaho Urologic Institute, PA | Meridian | Idaho | Recruiting |
| Saint Lukes Health System | Independence | Missouri | Active Not Recruiting |
| CHI Health Research Center | Omaha | Nebraska | Recruiting |
| Penn State University | Hershey | Pennsylvania | Recruiting |
| Hôpital de la Conception - Marseille | Marseille | France | Recruiting |
| CHU de Nantes | Nantes | France | Recruiting |
| Pitié Salpêtrière University Hospital Paris | Paris | France | Recruiting |
More Uromedica trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04248283 on ClinicalTrials.gov ↗ ← All trials in the USA